Want to see BDRX full AI Analyst Report?
Biodexa Pharmaceuticals (BDRX) Ratios
Biodexa Pharmaceuticals Ratios
BDRX's free cash flow for Q2 2026 was $-4.62M. For the 2026 fiscal year, BDRX's free cash flow was decreased by $-7.14K and operating cash flow was $-4.62M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.03 | 1.75 | 1.26 | 2.47 | 6.39 |
| Quick Ratio | 2.03 | 1.75 | 1.39 | 2.47 | 6.39 |
| Cash Ratio | 1.39 | 0.33 | 1.07 | 1.49 | 5.46 |
| Solvency Ratio | -0.90 | -0.87 | -1.16 | -3.17 | -2.06 |
| Operating Cash Flow Ratio | -0.88 | -2.44 | -1.23 | -3.71 | -3.26 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 5.66M | $ 2.35M | $ 1.17M | $ 2.33M | $ 9.30M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.05 | 0.04 | 0.11 | 0.06 |
| Debt-to-Equity Ratio | 0.01 | 0.09 | 0.10 | 0.20 | 0.07 |
| Debt-to-Capital Ratio | 0.01 | 0.08 | 0.09 | 0.16 | 0.07 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.59 | 1.78 | 2.25 | 1.75 | 1.24 |
| Debt Service Coverage Ratio | -116.57 | -411.90 | -164.76 | -140.17 | -113.93 |
| Interest Coverage Ratio | -120.77 | -429.02 | -195.46 | -168.53 | -159.05 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 75.56 | 1630.29 | 43711.26 | 52298.55 |
| Net Debt to EBITDA | 1.05 | 0.10 | 0.77 | 0.27 | 1.64 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | -967.45% | -631.19% | -705.19% |
| EBIT Margin | 0.00% | 0.00% | -1953.81% | -1206.72% | -1048.79% |
| EBITDA Margin | 0.00% | 0.00% | -1879.53% | -1181.83% | -979.07% |
| Operating Profit Margin | 0.00% | 0.00% | -2103.41% | -1277.83% | -1210.73% |
| Pretax Profit Margin | 0.00% | 0.00% | -1964.57% | -1214.31% | -1056.40% |
| Net Profit Margin | 0.00% | 0.00% | -1858.01% | -1095.28% | -944.64% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | -1858.01% | -1095.28% | -944.64% |
| Net Income Per EBT | 98.38% | 95.82% | 94.58% | 90.20% | 89.42% |
| EBT Per EBIT | 76.76% | 65.00% | 93.40% | 95.03% | 87.25% |
| Return on Assets (ROA) | -34.41% | -38.76% | -67.15% | -138.57% | -42.28% |
| Return on Equity (ROE) | -54.85% | -68.84% | -151.33% | -242.13% | -52.24% |
| Return on Capital Employed (ROCE) | -68.74% | -94.39% | -161.15% | -246.40% | -63.20% |
| Return on Invested Capital (ROIC) | -67.29% | -85.12% | -147.40% | -212.80% | -55.78% |
| Return on Tangible Assets | -49.90% | -62.72% | -93.13% | -138.72% | -42.28% |
| Earnings Yield | -0.34% | -357.42% | -4337.92% | -758.82% | -113.61% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.54 | 2.12 | 17.52 |
| Payables Turnover | 1.91 | 7.69 | 12.95 | 15.08 | 9.60 |
| Inventory Turnover | 0.00 | 0.00 | -5.78 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.67 | 0.84 | 0.50 |
| Asset Turnover | 0.00 | 0.00 | 0.04 | 0.13 | 0.04 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.18 | 0.11 | 0.07 |
| Cash Conversion Cycle | -191.53 | -47.46 | 583.07 | 147.59 | -17.20 |
| Days of Sales Outstanding | 0.00 | 0.00 | 674.44 | 171.80 | 20.84 |
| Days of Inventory Outstanding | 0.00 | 0.00 | -63.18 | 0.00 | 0.00 |
| Days of Payables Outstanding | 191.53 | 47.46 | 28.18 | 24.21 | 38.04 |
| Operating Cycle | 0.00 | 0.00 | 611.25 | 171.80 | 20.84 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.20 | -1237.79 | -22036.31 | -455061.98 | -387913.22 |
| Free Cash Flow Per Share | -0.20 | -1315.93 | -22885.35 | -459065.08 | -408574.38 |
| Dividend Paid and CapEx Coverage Ratio | -2757.74 | -15.84 | -25.95 | -113.68 | -18.77 |
| Capital Expenditure Coverage Ratio | -2757.74 | -15.84 | -25.95 | -113.68 | -18.77 |
| Operating Cash Flow Coverage Ratio | -88.59 | -16.87 | -14.71 | -11.29 | -7.84 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | -17.92 | -10.08 | -10.39 |
| Free Cash Flow Yield | -0.29% | -813.23% | -4344.05% | -704.70% | -131.67% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -210.59 | -0.28 | -0.02 | -0.13 | -0.88 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.43 | 1.44 | 8.32 |
| Price-to-Book (P/B) Ratio | 162.36 | 0.19 | 0.03 | 0.32 | 0.46 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -342.56 | -0.12 | -0.02 | -0.14 | -0.76 |
| Price-to-Operating Cash Flow Ratio | -342.69 | -0.13 | -0.02 | -0.14 | -0.80 |
| Price-to-Earnings Growth (PEG) Ratio | 2.36 | 0.00 | 0.00 | -0.00 | 0.01 |
| Enterprise Value Multiple | -227.62 | -0.07 | 0.75 | 0.15 | 0.79 |
| Enterprise Value | 1.84B | 660.88K | -5.34M | -1.20M | -4.48M |
| EV to EBITDA | -227.62 | -0.07 | 0.75 | 0.15 | 0.79 |
| EV to Sales | 0.00 | 0.00 | -14.03 | -1.72 | -7.76 |
| EV to Free Cash Flow | -340.99 | -0.05 | 0.75 | 0.17 | 0.71 |
| EV to Operating Cash Flow | -341.12 | -0.05 | 0.78 | 0.17 | 0.75 |
| Tangible Book Value Per Share | 0.21 | 270.15 | 5607.54 | 203770.66 | 674875.32 |
| Shareholders’ Equity Per Share | 0.42 | 840.13 | 15101.94 | 204158.06 | 674875.32 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.02 | 0.04 | 0.05 | 0.10 | 0.11 |
| Revenue Per Share | 0.00 | 0.00 | 1229.98 | 45131.71 | 37319.21 |
| Net Income Per Share | -0.23 | -578.36 | -22853.07 | -494318.18 | -352530.99 |
| Tax Burden | 0.98 | 0.96 | 0.95 | 0.90 | 0.89 |
| Interest Burden | 0.77 | 0.65 | 1.01 | 1.01 | 1.01 |
| Research & Development to Revenue | 0.00 | 0.00 | 10.67 | 7.31 | 8.05 |
| SG&A to Revenue | 0.00 | 0.00 | 11.40 | 6.50 | 5.10 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.07 | 0.18 | 0.15 |
| Income Quality | 0.84 | 2.14 | 0.96 | 0.92 | 1.10 |
Currency in GBP